These are this morning’s top day trader alerts and most active in price and volume. We have more detailed analysis and data on price and volume with links through to each at…
Reuters: Microsoft’s (MSFT) results and forecast were weak. Reuters:Â Â CIT (CIT) may sell its aviation finance business. Reuters:Â Â Fatigue at the Fed is leading to questions about its expanded role. Reuters:Â Â Twitter…
Bristol Myers Inc. (NYSE: BMY) plans to spend $2.4 billion to buy partner Medarex Inc. (Nasdaq: MEDX). It will get a great deal beyond the cancer monoclonal antibody that developed together. The Medarex…
The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis…
Reuters:Â Â Obama says healthcare reform is essential to the recovery. Reuters:Â Â CIT (CIT) bond advisers will push for Chapter 11. Reuters:Â Â Democrats will fight with banks on consumer agency. Reuters:Â Â Amazon (AMZN)…
These are the top analyst downgrades and cautious research calls we have seen from Wall Street this Thursday morning: ArQule (ARQL) Cut to Sell at UBS. ASML (ASML) Cut to Neutral at…
We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.  This is broken down in drug…
We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a brief…
Medarex, Inc. (NASDAQ: MEDX) announced that its wholly owned MDX-1100 met its primary endpoints for patients receiving methotrexate in a Phase II ‘proof of concept’ trial in patients with active rheumatoid arthritis. …
Douglas A. McIntyre This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and…
These are ten of the top pre-market early bird upgrades and downgrades we are seeing from analysts this Friday morning: H.B. Fuller (NYSE: FUL) Raised to Overweight at JPMorgan. Och-Ziff Capital (NYSE:…
There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II…
These are some of the early bird analyst downgrades and negative calls we are seeing this Thursday morning with more than two hours to the open: AudioCodes (AUDC) cut to neutral at…
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) falling today after first quarter earnings showed wider losses than first quarter 2007. Net loss was $8.7 million compared to a loss of $3.8 million in…
Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma. The company says that there are key differences between…
